Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

HSBC double downgraded Eli Lilly (LLY) to Reduce from Buy with a price target of $700, down from $1,150. The market has assumed a significant market share for Lilly, but with potential economic ...

HSBC suggests reducing Bajaj Housing Finance ... to become the primary supplier given capacity addition.Orforglipron, Eli Lilly’s potential best-in-class oral GLP-1, is the next addition in ...

HSBC is cautious on pharma stock Eli Lilly (NYSE: LLY), lowering the rating to “reduce” from “buy” amid risk headwinds.

Stocktwits - HSBC on Monday double downgraded Eli Lilly and Co. (NYSE:LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to $700 from $1,150. The new price target represents a 21% ...